Compare GPRK & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPRK | SLN |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | Colombia | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 649.0M | 678.0M |
| IPO Year | 2009 | 2010 |
| Metric | GPRK | SLN |
|---|---|---|
| Price | $11.02 | $12.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $8.50 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 1.1M | 666.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $559,000.00 |
| Revenue This Year | $39.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.75 | $4.19 |
| 52 Week High | $13.13 | $17.58 |
| Indicator | GPRK | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 41.52 |
| Support Level | $9.20 | $4.70 |
| Resistance Level | $11.77 | $15.28 |
| Average True Range (ATR) | 0.60 | 0.75 |
| MACD | -0.06 | -0.28 |
| Stochastic Oscillator | 30.21 | 6.92 |
GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.